5-HT1A receptor agonist flesinoxan enhances Fos immunoreactivity in rat central amygdala, bed nucleus of the stria terminalis and hypothalamus

The European Journal of Neuroscience
J C CompaanB Olivier

Abstract

5-Hydroxytryptamine-1A (5-HT1A) receptor agonists, including flesinoxan, reduce anxiety and activate the hypothalamus-pituitary-adrenal (HPA) axis under basal conditions. In order to investigate the underlying neural mechanisms we investigated immunoreactivity for the immediate early gene protein product Fos (Fos-ir) in rat brains 1 h after flesinoxan treatment (0.0, 0.3 or 3.0 mg/kg p.o.). Typically, 5-HT1A receptor-containing brain areas, such as the dorsal raphe nuclei, hippocampus, septum, diagonal band and the cortical and basomedial amygdala, do not show Fos-ir. Apparently, binding of flesinoxan at the 5-HT1A receptor does not directly lead to activation of c-fos in the cell, probably due to its negative coupling to adenylate cyclase. However, in typically non-5HT1A receptor-containing brain areas Fos-ir is increased due to flesinoxan treatment, as in the paraventricular nucleus of the hypothalamus (PVN), the dorsolateral part of the bed nucleus of the stria terminalis (BNSTdl) and the central amygdala (CeA). Flesinoxan-treated rats also exhibited higher plasma corticosterone levels than vehicle-treated animals, which suggests the involvement of corticotropin-releasing hormone (CRH) or vasopressin in the hypothalamus. Aft...Continue Reading

References

Jan 1, 1992·Physiological Reviews·B L Jacobs, E C Azmitia
Nov 1, 1991·Peptides·J H LiveseyR A Donald
Jul 1, 1988·Pharmacology, Biochemistry, and Behavior·R W FullerD W Robertson
Aug 1, 1986·Naunyn-Schmiedeberg's Archives of Pharmacology·R MarksteinG Engel
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
May 4, 1984·Science·J Axelrod, T D Reisine
Nov 1, 1994·Synapse·S J Peroutka
Aug 1, 1994·Pharmacology, Biochemistry, and Behavior·R J RodgersA Davies
Apr 1, 1994·Pharmacology, Biochemistry, and Behavior·C E YbemaB Olivier
Jan 1, 1994·Physiology & Behavior·T J ZethofB Olivier
Jan 1, 1993·International Clinical Psychopharmacology·P GrofD Bradford
Apr 1, 1993·Frontiers in Neuroendocrinology·F A Antoni
Jan 1, 1993·Brain Research Bulletin·B H Li, N E Rowland
Jan 1, 1993·Journal of Psychopharmacology·J F Deakin

❮ Previous
Next ❯

Citations

Jul 17, 2013·Psychopharmacology·Helene GelezFrancois Giuliano
Jan 12, 2011·Sleep & Breathing = Schlaf & Atmung·Stephane BesnardChristian Gestreau
Sep 12, 2000·European Journal of Pharmacology·R M SibugE R De Kloet
Nov 26, 2002·European Journal of Pharmacology·Minke E JongsmaJakob Korf
Apr 18, 1997·European Journal of Pharmacology·J C CompaanB Olivier
Sep 17, 1998·Brain Research Bulletin·I Kostoglou-Athanassiou, M L Forsling
Aug 26, 1998·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J G VeeningB Olivier
Jan 28, 2005·The European Journal of Neuroscience·Heidi E W DaySerge Campeau
Apr 19, 2008·European Journal of Pharmacology·Christiaan H VinkersLucianne Groenink
Jul 9, 2004·Annals of the New York Academy of Sciences·Jens D MikkelsenAlexander Kiss
Apr 29, 2008·Neuroscience and Biobehavioral Reviews·Andrew Holmes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.